Tumour suppression by p53: the importance of apoptosis and cellular senescence

被引:166
作者
Zuckerman, Valentina [1 ]
Wolyniec, Kamil [2 ]
Sionov, Ronit V. [1 ]
Haupt, Sue [2 ]
Haupt, Ygal [1 ,2 ]
机构
[1] Hebrew Univ Jerusalem, Hadassah Med Sch, Lautenberg Ctr Gen & Tumor Immunol, IL-91120 Jerusalem, Israel
[2] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic 3002, Australia
基金
澳大利亚国家健康与医学研究理事会; 以色列科学基金会;
关键词
apoptosis; senescence; tumour suppression; p53; p73; cancer therapy; miRNA; WILD-TYPE P53; REGULATES P53-DEPENDENT APOPTOSIS; PLASMINOGEN-ACTIVATOR INHIBITOR-1; HUMAN-DIPLOID FIBROBLASTS; RAS-INDUCED SENESCENCE; LI-FRAUMENI-SYNDROME; REGRESSION IN-VIVO; MUTANT P53; DNA-DAMAGE; ONCOGENIC RAS;
D O I
10.1002/path.2584
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
p53 is regarded as a central player in tumour suppression, as it controls programmed cell death (apoptosis) as well as cellular senescence. While apoptosis eliminates cells at high risk for oncogenic transformation, senescence acts as a barrier to tumourigenesis by imposing irreversible cell cycle arrest. p53 can act directly or indirectly at multiple levels of the tumour suppression network by invoking a myriad of mechanisms. p53 induces the extrinsic and intrinsic apoptotic pathways at multiple steps to ensure an efficient death response. This response involves transcriptional activation or repression of target genes, as well as the recently identified microRNAs, and transcription-independent functions. Importantly, p53 loss of function is required for tumour maintenance. Therefore, therapeutic strategies aimed at reactivation of p53 in tumours emerge as a promising approach for the treatment of cancer patients. Copyright (C) 2009 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:3 / 15
页数:13
相关论文
共 145 条
[1]
Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1 [J].
Ambrosini, G. ;
Sambol, E. B. ;
Carvajal, D. ;
Vassilev, L. T. ;
Singer, S. ;
Schwartz, G. K. .
ONCOGENE, 2007, 26 (24) :3473-3481
[2]
A critical role for telomeres in suppressing and facilitating carcinogenesis [J].
Artandi, SE ;
DePinho, RA .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2000, 10 (01) :39-46
[3]
A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo [J].
Bell, Helen S. ;
Dufes, Christine ;
O'Prey, Jim ;
Crighton, Diane ;
Bergamaschi, Danielle ;
Lu, Xin ;
Schatzlein, Andreas G. ;
Vousden, Karen H. ;
Ryan, Kevin M. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (04) :1008-1018
[4]
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy [J].
Blandino, G ;
Levine, AJ ;
Oren, M .
ONCOGENE, 1999, 18 (02) :477-485
[5]
Expression of p53 isoforms in squamous cell carcinoma of the head and neck [J].
Boldrup, Linda ;
Bourdon, Jean-Christophe ;
Coates, Philip J. ;
Sjostrom, Bjorn ;
Nylander, Karin .
EUROPEAN JOURNAL OF CANCER, 2007, 43 (03) :617-623
[6]
p53 isoforms can regulate p53 transcriptional activity [J].
Bourdon, JC ;
Fernandes, K ;
Murray-Zmijewski, F ;
Liu, G ;
Diot, A ;
Xirodimas, DP ;
Saville, MK ;
Lane, DP .
GENES & DEVELOPMENT, 2005, 19 (18) :2122-2137
[7]
INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence [J].
Brookes, S ;
Rowe, J ;
Ruas, M ;
Llanos, S ;
Clark, PA ;
Lomax, M ;
James, MC ;
Vatcheva, R ;
Bates, S ;
Vousden, KH ;
Parry, D ;
Gruis, N ;
Smit, N ;
Bergman, W ;
Peters, G .
EMBO JOURNAL, 2002, 21 (12) :2936-2945
[8]
Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation [J].
Bulavin, DV ;
Saito, S ;
Hollander, MC ;
Sakaguchi, K ;
Anderson, CW ;
Appella, E ;
Fornace, AJ .
EMBO JOURNAL, 1999, 18 (23) :6845-6854
[9]
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis [J].
Bykov, VJN ;
Zache, N ;
Stridh, H ;
Westman, J ;
Bergman, J ;
Selivanova, G ;
Wiman, KG .
ONCOGENE, 2005, 24 (21) :3484-3491
[10]
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound [J].
Bykov, VJN ;
Issaeva, N ;
Shilov, A ;
Hultcrantz, M ;
Pugacheva, E ;
Chumakov, P ;
Bergman, J ;
Wiman, KG ;
Selivanova, G .
NATURE MEDICINE, 2002, 8 (03) :282-288